PRMT9 and leukemia: Rag2−/− (Fig. 5b,e) or NSGS (Fig. 5c,f) mice bearing Prmt9 KD transplants survived significantly longer than mice with Prmt9 WT transplants, but succumbed to leukemia within 60 days (Fig. 5e,f).